
|Articles|December 1, 2007
Oncology NEWS International
- Oncology NEWS International Vol 16 No 12
- Volume 16
- Issue 12
ASA404 lung ca trial expanded
ASA404 lung cancer trial expanded
Advertisement
LONDONAntisoma plc announced that its licensing partner Novartis plans to start a pivotal phase III trial of ASA404 in non-small-cell lung cancer in early 2008. This trial has been expanded to include patients with nonsquamous as well as squamous disease, a change that more than doubles the population of NSCLC patients addressed by the trial.
Articles in this issue
about 18 years ago
Third-line single-agent cetuximab ups overall survivalabout 18 years ago
Modern multislice CT propels pancreas imaging forwardabout 18 years ago
Sorafenib gets ok for liver cancerabout 18 years ago
Celgene to acquire Pharmionabout 18 years ago
Novacea halts ASCENT-2 trialabout 18 years ago
RT/temozolomide raises possibility of cure in glioblastomaabout 18 years ago
Brachytherapy as effective in younger as in older menabout 18 years ago
MMA not harming patientsabout 18 years ago
Kinase inhibitor may prevent RT-induced lung injuryabout 18 years ago
FDA approves lower starting dose for dasatinib for CMLNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Combo Reduces Progression, Death By 35% in Metastatic TNBC
2
FDA Approves Liquid Biopsy CDx for Encorafenib Regimen in BRAF V600E+ CRC
3
BNT113 Granted Fast Track Designation in HPV16-Positive HNSCC
4
Decoding the Top Moments in Prostate Cancer Management From 2025
5





































